Cutting-edge Gene Therapy Offers Hope for Incurable Cancers

Amazing base-editing treatment works for a teenager suffering from cancer when all other treatments fail.

Highlights:

A 13 year old girl with cancer is the first person in the world to receive ‘base-edited’ cells after chemotherapy and bone marrow transplant failed
As a last resort, researchers attempted a groundbreaking experimental therapy in which donated immune T-cells were genetically edited to target her cancer //
She is now cancer-free, which gives hope to other children suffering from the same disease

Researchers have used a revolutionary new type of gene therapy to treat a young teenager with relapsed T-cell leukemia. The administration of the technique -the first of its kind in the world, has raised hopes that it could soon help tackle other childhood cancers and serious diseases. The technique, known as base-editing, is the first time a cancer treatment has altered the fundamental building blocks of DNA.

The teenager named Alyssa, from Leicester, was diagnosed with T-cell acute lymphoblastic leukemia, which could not be treated with chemotherapy or a bone marrow transplant. With no options left, doctors at Great Ormond Street Hospital in London, attempted a revolutionary experimental therapy in which donated immune T-cells were genetically edited to target her cancer.

Poor Immune Response in Many Double-vaccinated Blood Cancer Patients: Study
A new research has revealed that more than 50% of double vaccinated blood cancer patients have been left with little protection against COVID-19.

‘A teenager in the UK is the first person in the world to receive ‘base-edited’ cells that could be the next big thing in cancer medicine.’

Experts changed the genetic code of immune cells to allow them to hunt down and kill cancerous T-cells while leaving the healthy ones alone..

After nearly a month, Alyssa was in remission, and after a second bone marrow transplant to restore her immune system, the leukemia is now undetectable. She is recovering and is being monitored periodically.

“This is a great demonstration of how, with expert teams and infrastructure, we can link cutting-edge technologies in the lab with real results in the hospital for patients. It's our most sophisticated cell engineering so far and paves the way for other new treatments and ultimately better futures for sick children”, said researchers.

Base-Editing for Treatment of Cancer

To create the cells, healthy donor T-cells needed to be engineered in four stages. Firstly, receptors needed to be removed from the donated cells to avoid rejection.

New T-cell Leukemia Target Mutations Identified
Large-scale genomic analysis identifies previously unknown putative genetic mutations that lead to T- cell acute lymphoid leukemia.

Next, a glycoprotein known as CD7 identifies them as T-cells was removed so that the engineered cells did not end up destroying each other.

In the third step, a second glycoprotein, called CD52, was removed to make the edited cells invisible to drugs given to the patient during the treatment process.

Finally, a receptor was added, allowing the cells to recognise leukemic T-cells.These changes were achieved by “base editing” - chemically converting single nucleotide bases or letters of the DNA code, which carry instructions.

For example, changing the nucleotide bases in the gene for CD7 from a cytosine to a thymine creates the equivalent of a genetic full stop, and stops the immune system from attacking T-cells.

T Cell Immunotherapy Offers Positive Results in Children and Adults With Leukemia
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell

The 13 year old was diagnosed with T-cell leukemia in May 2021, after a long period of what the family thought were colds, viruses, and general tiredness.

Despite months of treatment in hospitals, doctors were unable to get her cancer under control and into remission. The teenager’s parents are over the moon with regards to the treatment and hope that the research works and can be offered to more children suffering from the same disease.

Ongoing Treatment Trial for Base-Editing

The clinical trial for this treatment is currently open and aims to recruit up to 10 patients with T-cell leukemia who have exhausted all conventional treatment options.

If shown to be successful, the bone marrow transplant and T-cell therapy can be offered to children earlier when they are less sick.

This result proves to be quite amazing, although it is still in its preliminary stage and needs further research, which must be monitored and confirmed over the next few months.

Source-Medindia